FindTrial
Sign In

The development of individualized medication model of valproic acid in epileptic based on sparse plasma drug concentration

The development of individualized medication model of valproic acid in epileptic based on sparse plasma drug concentration

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062242
Enrollment
Unknown
Registered
2022-07-31
Start date
2022-07-30
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epileptic

Interventions

Experimental group:Valproate tablets, valproate sustained-release tablets or valproate injection

Sponsors

Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. Epileptic patients using valproate tablets, valproate sustained-release tablets or valproate injection; 2. Stable concentration was reached (continuous administration time of oral valproate >7 days or continuous administration time of injection >3 days); 3. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with abnormal liver and kidney function; 2. Patients taking drugs other than antiepileptic drugs that affect the blood concentration of valproate.

Design outcomes

Primary

MeasureTime frame
Valproic acid concentration in plasma;—

Countries

China

Contacts

Public ContactYang Guoping
syy09826@163.om+86 13974817168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026